IRADIMED CORP IRMD

Healthcare SIC 3841 - Surgical & Medical Instruments & Apparatus NAICS Manufacturing › Miscellaneous Manufacturing › Medical Equipment and Supplies Manufacturing › Surgical and Medical Instrument Manufacturing derived Nasdaq

IRADIMED CORPORATION ("IRadimed", the "Company," "we," "us," "our" or similar terms) develops, manufactures, markets and distributes Magnetic Resonance Imaging ("MRI") compatible medical devices and related accessories, disposables and services relating to them. We were originally incorporated in Oklahoma under the name IRI Development, Inc. in 1992, and we merged our Oklahoma corporation into the newly formed Delaware corporation, IRADIMED CORPORATION, in April 2014.

We are the only known provider of a non-magnetic intravenous ("IV") infusion pump system that is specifically designed to be safe for use during MRI procedures and operates dependably in magnetic fields up to 15,000 gauss. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components which can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium 3870 MRI Compatible IV Infusion Pump System, introduced in 2025, has been designed with a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts, touch screen user interface, and other special features to safely and predictably deliver anesthesia and other critical care IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe and dependable fluid delivery before, during and after an MRI scan, which is important to critically ill patients who cannot be removed from their vital medications, and children and infants who must generally be sedated to remain immobile during an MRI scan.

Last close 85.82 2026-10-23
Market cap $1.10B 2026-06-30 share count
52-week range 75.75 - 107.90

Valuation FY2025 figures against the last close

P/S13.1x
P/E49.0x
P/FCF63.9x
EV/EBITDA40.2x
Dividend yield1.4%
Diluted EPS1.75

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • United States
  • International
Revenue by geography, 2 categories over 2 years. The same figures are in the table below. FY2025 United States, FY2025: 70.6M (84.2%) 84% United States International, FY2025: 13.3M (15.8%) 16% International FY2024 United States, FY2024: 60.6M (82.7%) 83% International, FY2024: 12.6M (17.3%) 17%
Region FY2025FY2024
United States $70.6M $60.6M
International $13.3M $12.6M

As the company reported it, from the “Revenue - Information by geographic region (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $83.8M$73.2M$65.6M$53.3M$41.8M$31.7M$38.5M$30.4M$23.1M$32.5M
Cost of revenue $19.5M$16.9M$15.4M$12.0M$9.8M$8.1M$8.8M$7.2M$5.6M$6.2M
Gross profit $64.3M$56.4M$50.2M$41.3M$32.0M$23.6M$29.7M$23.2M$17.5M$26.3M
R&D $3.0M$2.8M$2.9M$2.3M$1.9M$1.9M$1.4M$1.5M$1.7M$1.3M
SG&A $17.8M$15.9M$15.1M$10.7M$9.8M$12.3M$10.5M$8.7M$9.0M$8.8M
Total operating expenses $38.2M$34.4M$30.1M$25.7M$22.2M$24.3M$21.1M$17.2M$16.2M$15.4M
Operating income $26.1M$22.0M$20.0M$15.6M$9.8M-$756.1K$8.6M$6.0M$1.3M$10.9M
Pre-tax income $28.4M$24.3M$21.7M$16.2M$9.8M-$616.9K$9.0M$6.2M$1.4M$11.0M
Income tax $5.9M$5.0M$4.5M$3.4M$510.8K$2.0M$587.6K$106.1K$896.6K$3.7M
Net income $22.5M$19.2M$17.2M$12.8M$9.3M$1.4M$9.6M$6.3M$499.8K$7.2M
EPS, basic 1.771.521.361.020.760.110.850.590.050.67
EPS, diluted 1.751.501.351.020.740.110.780.520.040.60
Shares, diluted (wtd. avg.) 12.9M12.8M12.7M12.6M12.6M12.4M12.3M12.1M11.7M12.0M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $51.2M$52.2M$49.8M$58.0M$62.0M$50.1M$43.5M$28.0M$18.2M$17.7M
Receivables $13.7M$10.6M$12.2M$13.3M$5.1M$4.6M$7.3M$4.2M$3.8M$3.8M
Inventory $11.6M$10.4M$12.8M$5.4M$4.3M$3.9M$3.6M$4.1M$4.2M$3.9M
Total current assets $81.2M$75.2M$76.0M$77.5M$76.2M$63.7M$59.0M$44.5M$35.1M$33.9M
Property, plant and equipment $23.9M$16.8M$9.3M$2.4M$2.1M$2.1M$2.1M$1.9M$1.9M$1.5M
Other intangibles $3.4M$3.1M$2.5M$2.1M$1.1M$960.9K$860.1K$832.5K$885.5K$918.7K
Total assets $108.8M$98.3M$92.2M$85.5M$82.9M$71.1M$66.7M$48.4M$39.0M$37.2M
Accounts payable $1.8M$1.9M$1.9M$1.8M$782.9K$657.1K$993.7K$772.5K$656.7K$1.1M
Total current liabilities $10.2M$8.5M$16.3M$8.6M$6.8M$4.9M$5.9M$4.7M$4.1M$3.7M
Total liabilities $14.2M$11.5M$20.7M$11.8M$10.7M$9.7M$11.2M$6.5M$6.1M$5.3M
Retained earnings $64.2M$56.8M$43.3M$47.3M$47.0M$37.7M$36.3M$26.7M$20.4M$19.9M
Total equity $94.6M$86.8M$71.4M$73.7M$72.2M$61.4M$55.5M$41.9M$32.9M$31.9M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $24.9M$25.6M$13.5M$10.0M$11.3M$5.8M$10.2M$7.4M$3.4M$9.4M
Depreciation and amortisation $1.2M$818.0K$765.2K$670.7K$1.4M$1.3M$1.2M$1.1M$1.3M$955.8K
Stock-based compensation $2.9M$2.5M$2.2M$1.4M$1.5M$4.0M$1.9M$1.8M$2.5M$1.8M
Capital expenditure $7.8M$8.0M$7.4M$823.0K$482.3K$443.0K$368.3K$228.3K$775.6K$780.8K
Investing cash flow -$8.4M-$8.8M-$8.0M-$1.4M$648.2K$247.0K$3.2M$1.5M-$1.0M-$1.9M
Financing cash flow -$17.6M-$14.3M-$13.7M-$12.7M$24.4K$522.5K$2.0M$929.9K-$1.9M-$9.1M
Dividends paid $15.0M$13.7M$13.2M$12.6M——————
Buybacks ————————$1.8M$10.0M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-028903.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. 0 25M 50M 75M 100M Revenue, FY2016: 32.5M Gross profit, FY2016: 26.3M Net income, FY2016: 7.2M Revenue, FY2017: 23.1M Gross profit, FY2017: 17.5M Net income, FY2017: 499.8K Revenue, FY2018: 30.4M Gross profit, FY2018: 23.2M Net income, FY2018: 6.3M Revenue, FY2019: 38.5M Gross profit, FY2019: 29.7M Net income, FY2019: 9.6M Revenue, FY2020: 31.7M Gross profit, FY2020: 23.6M Net income, FY2020: 1.4M Revenue, FY2021: 41.8M Gross profit, FY2021: 32M Net income, FY2021: 9.3M Revenue, FY2022: 53.3M Gross profit, FY2022: 41.3M Net income, FY2022: 12.8M Revenue, FY2023: 65.6M Gross profit, FY2023: 50.2M Net income, FY2023: 17.2M Revenue, FY2024: 73.2M Gross profit, FY2024: 56.4M Net income, FY2024: 19.2M Revenue, FY2025: 83.8M Gross profit, FY2025: 64.3M Net income, FY2025: 22.5M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $32.5M $23.1M $30.4M $38.5M $31.7M $41.8M $53.3M $65.6M $73.2M $83.8M
Gross profit $26.3M $17.5M $23.2M $29.7M $23.6M $32.0M $41.3M $50.2M $56.4M $64.3M
Net income $7.2M $499.8K $6.3M $9.6M $1.4M $9.3M $12.8M $17.2M $19.2M $22.5M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Other event Item 8.01
  • Results announced Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Results announced Item 2.02
  • Shareholder vote Item 5.07

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 3841

TickerCompanyMarket capP/ERevenue growth
SYK STRYKER CORP $117.81B 36.6x 11.2%
MMM 3M CO $89.46B 28.9x 1.5%
BSX BOSTON SCIENTIFIC CORP $66.22B 23.6x 19.9%
BDX BECTON DICKINSON & CO $54.18B 34.2x 8.2%
RMD RESMED INC $36.48B 24.2x 9.9%
DXCM DEXCOM INC $29.41B 37.3x 15.6%
MDLN Medline Inc. $29.20B — 11.5%
WST WEST PHARMACEUTICAL SERVICES INC $27.60B 57.8x 6.3%